Table 2.

Crude and adjusted hazard ratios (95% confidence intervals) for mortality (overall and pre-ESRD mortality) according to glycated hemoglobin values

Overall Mortality
HbA1c (%)No. of Events/nCrude HRmGFR-Adjusted HRFully Adjusted HRa
Tertiles
 1 (<5.3)27/3351 (ref)1 (ref)1 (ref)
 2 (5.3–5.7)30/3901.13 (0.67 to 1.91)1.20 (0.71 to 2.03)1.07 (0.60 to 1.88)
 3 (5.7–6.5)52/4402.05 (1.28 to 3.29)2.18 (1.36 to 3.51)1.79 (1.06 to 3.00)
P value for trend0.002<0.0010.02
Continuous109/11651.88 (1.24 to 2.86)1.98 (1.31 to 2.98)1.66 to (1.07 to 2.58)
P value0.0030.0010.02
Pre-ESRD Mortality
HbA1c (%)No. of Events/nCrude HRmGFR-Adjusted HRFully Adjusted HRa
Tertiles
 1 (<5.3)14/3351 (ref)1 (ref)1 (ref)
 2 (5.3–5.7)22/3901.39 (0.71 to 2.72)1.36 (0.69 to 2.65)1.23 (0.60 to 2.54)
 3 (5.7–6.5)36/4402.38 (1.28 to 4.42)2.28 (1.23 to 4.22)2.00 (1.02 to 3.92)
P value for trend0.0040.010.03
Continuous72/11652.16 (1.27 to 3.68)2.07 (1.22 to 3.51)1.85 (1.05 to 3.24)
P value0.010.010.03
  • HbA1c, glycated hemoglobin; ref, reference; HR, hazard ratio; mGFR, measured GFR.

  • a Adjusted for measured GFR, age, sex, body mass index (<19, 20–24, 25–29, ≥30), race (black/other), urinary protein/creatinine ratio (log), elevated BP (>140/90 mmHg), history of cardiovascular disease (yes or no), smoking status (current smoker, former smoker, or never smoker), angiotensin-converting enzyme inhibitor or antireceptor blocker treatment, and serum albumin (>3.5 g/dl or <3.5 g/dl).